Impact of a low nicotine standard for smoked tobacco in real life
Official title: Assessing the real-world impact of a low nicotine product standard for smoked tobacco in New Zealand
Funded at Wake Forest University Health Sciences · NIH-11455246 · Data updated 2026-11-12
This project follows adults who smoke daily to see how a nationwide, very low nicotine standard would affect their smoking, health, and well-being over several years.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $6,934 |
| NIH project number | 3R01DA058264-04S2 |
| Project ID | NIH-11455246 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21+ who smoke daily or nearly daily and are willing to participate in a long-term observational study.
✕Less likely to help
Individuals not planning to participate in long-term follow-up or who do not smoke could not benefit directly.
What this research studies
Researchers will track 1,500 adults who smoke daily or almost daily over about 3.5 years, using online surveys, biological markers, physical assessments, and interviews to understand changes in smoking behavior and health after a potential nicotine reduction policy. The study combines quantitative data with patient experiences to capture real-world effects of a low nicotine standard on daily use, dependence, and health outcomes. It builds on prior clinical trials but focuses on long-term, real-world settings and medical records to provide a fuller picture. Participants will contribute online information, biomarker samples, and periodic check-ins, with qualitative interviews to explore personal and social factors influencing behavior.
Why it matters
Potential benefit: If successful, findings could inform policy decisions that help reduce smoking and improve health on a population level.
How similar studies have gone: Prior trials show short-term reductions in exposure and dependence, but this study examines longer-term, real-world impacts.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Denlinger-Apte, Rachel — Wake Forest University Health Sciences
- Study coordinator: Denlinger-Apte, Rachel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.